Proteomic Investigation of COVID-19 Severity During the Tsunamic Second Wave in Mumbai
- PMID: 37378767
- DOI: 10.1007/978-3-031-28012-2_9
Proteomic Investigation of COVID-19 Severity During the Tsunamic Second Wave in Mumbai
Abstract
Maharashtra was severely affected during the noxious second wave of COVID-19, with the highest number of cases recorded across India. The emergence of new symptoms and dysregulation of multiple organs resulted in high disease severity during the second wave which led to increased difficulties in understanding the molecular mechanisms behind the disease pathology. Exploring the underlying factors can help to relieve the burden on the medical communities to some extent by prioritizing the patients and, at the same time, opening avenues for improved treatments. In the current study, we have performed a mass-spectrometry-based proteomic analysis to investigate the disease pathology using nasopharyngeal swab samples collected from the COVID-19 patients in the Mumbai region of Maharashtra over the period of March-June 2021, the peak of the second wave. A total of 59 patients, including 32 non-severe and 27 severe cases, were considered for this proteomic study. We identified 23 differentially regulated proteins in severe patients as a host response to infection. In addition to the previously identified innate mechanisms of neutrophil and platelet degranulation, this study revealed significant alterations of anti-microbial peptide pathways in severe conditions, illustrating its role in the severity of the infectious strain of COVID-19 during the second wave. Furthermore, myeloperoxidase, cathepsin G, and profilin-1 were identified as potential therapeutic targets of the FDA-approved drugs dabrafenib, ZINC4097343, and ritonavir. This study has enlightened the role of the anti-microbial peptide pathway associated with the second wave in India and proposed its importance in potential therapeutics for COVID-19.
Keywords: COVID-19; Host response; MRM; Nasopharyngeal swab; Proteomics; Second wave; Severity markers.
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
References
-
- WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int . Accessed 19 Oct 2021
-
- Yadav R, Acharjee A, Salkar A, et al (2021) Mumbai mayhem of COVID-19 pandemic reveals important factors that influence susceptibility to infection. EClinicalMedicine 35:100841. https://doi.org/10.1016/j.eclinm.2021.100841 - DOI - PubMed - PMC
-
- Musuuza JS, Watson L, Parmasad V, et al (2021) Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One 16(5):e0251170. https://doi.org/10.1371/journal.pone.0251170 - DOI - PubMed - PMC
-
- Kaur SP, Gupta V (2020) COVID-19 Vaccine: A comprehensive status report. Virus Res 288:198114. https://doi.org/10.1016/j.virusres.2020.198114 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
